J. Christopher Naftzger

Executive

Nabriva Therapeutics plcArbutus Biopharma Corp

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 1 saleMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€3,647

▼ Sales (1 ops.)

€36k

Latest filing published 19 Feb 2025 for Arbutus Biopharma Corp.

Filing timeline

BuySale

J. Christopher Naftzger

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

J. Christopher Naftzger: trading record in brief

J. Christopher Naftzger (chief executive) discloses dealings in 2 companies, chiefly Arbutus Biopharma Corp and Nabriva Therapeutics plc. The record holds 4 filings, for trades running from 27 December 2021 to 14 February 2025.

Market trades split into 1 purchase (€3,647) and 1 sale (€36k). On balance, insiders were net sellers of €32k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants. In 2025 alone, the filings show no purchases and 1 sale.

On 19 February 2025 came the latest disclosure, a share grant in Arbutus Biopharma Corp. The clock since the last published purchase (28 December 2021) now reads 1,761 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.